Hyperbilirubinemia

Summary

Hyperbilirubinemia (MONDO:0024288) is a disease with 10 cohort genes and 30 clinical trials. The dominant Reactome pathway is Glucuronidation (7 cohort genes). Top therapeutic interventions include glycerin, levocarnitine, and stannsoporfin.

At a glance

• Cohort genes: 10
• ClinVar variants: 19
• Clinical trials: 30

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hyperbilirubinemia
Mondo ID	MONDO:0024288
MeSH	D006932
SNOMED CT	14783006
UMLS	C0311468
MedGen	86321
Is cancer (heuristic)	no

Also known as: hyperbilirubinemia

Data availability: 19 ClinVar variants.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › bilirubin metabolism disease › hyperbilirubinemia

Related subtypes (1): inborn disorder of bilirubin metabolism

Subtypes (2): hereditary hyperbilirubinemia, neonatal jaundice due to ABO incompatibility

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

19 retrieved; paginated sample, class counts are floors:

9 uncertain significance, 3 pathogenic, 3 conflicting classifications of pathogenicity, 2 pathogenic/likely pathogenic, 2 conflicting classifications of pathogenicity; other

ClinVar	Variant (HGVS)	Gene	Classification	Review
1170	NM_000505.4(F12):c.983C>G (p.Thr328Arg)	F12	Pathogenic	criteria provided, single submitter
160229	NM_000463.3(UGT1A1):c.1084+1G>T	UGT1A	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
12281	NM_000463.3(UGT1A1):c.1456T>G (p.Tyr486Asp)	UGT1A10	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
212544	NM_000463.3(UGT1A1):c.238_239insGTAC (p.Pro80fs)	UGT1A6	Pathogenic	criteria provided, multiple submitters, no conflicts
212545	NM_000463.3(UGT1A1):c.722_723del (p.Glu241fs)	UGT1A6	Pathogenic	criteria provided, multiple submitters, no conflicts
160232	NM_000463.3(UGT1A1):c.1413G>A (p.Ala471=)	UGT1A	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
160234	NM_000463.3(UGT1A1):c.141C>T (p.Ile47=)	UGT1A3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
160239	NM_000463.3(UGT1A1):c.674T>G (p.Val225Gly)	UGT1A3	Conflicting classifications of pathogenicity; other	criteria provided, conflicting classifications
160241	NM_000463.3(UGT1A1):c.996+15T>C	UGT1A5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
212543	NM_000463.3(UGT1A1):c.1091C>T (p.Pro364Leu)	UGT1A9	Conflicting classifications of pathogenicity; other	criteria provided, conflicting classifications
4755463	NM_032038.3(SPNS1):c.143_146dup (p.Ile50fs)	SPNS1	Uncertain significance	criteria provided, single submitter
4755464	NM_032038.3(SPNS1):c.1247C>G (p.Ser416Cys)	SPNS1	Uncertain significance	criteria provided, single submitter
160233	NM_000463.3(UGT1A1):c.141C>A (p.Ile47=)	UGT1A	Uncertain significance	criteria provided, single submitter
160237	NM_000463.3(UGT1A1):c.476T>C (p.Ile159Thr)	UGT1A	Uncertain significance	criteria provided, single submitter
160236	NM_000463.3(UGT1A1):c.322C>T (p.Arg108Cys)	UGT1A5	Uncertain significance	criteria provided, multiple submitters, no conflicts
160230	NM_000463.3(UGT1A1):c.1231G>T (p.Val411Leu)	UGT1A6	Uncertain significance	criteria provided, multiple submitters, no conflicts
160240	NM_000463.3(UGT1A1):c.748T>C (p.Ser250Pro)	UGT1A7	Uncertain significance	criteria provided, multiple submitters, no conflicts
160231	NM_000463.3(UGT1A1):c.1354G>T (p.Val452Leu)	UGT1A8	Uncertain significance	criteria provided, multiple submitters, no conflicts
160238	NM_000463.3(UGT1A1):c.479T>A (p.Val160Glu)	UGT1A8	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
F12	Orphanet:100054	F12-related hereditary angioedema with normal C1Inh
F12	Orphanet:330	Congenital factor XII deficiency
F12	Orphanet:617919	F12-associated cold autoinflammatory syndrome

Cohort genes → proteins

10 cohort genes, 9 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	10

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
UGT1A	HGNC:12529			UDP glucuronosyltransferase family 1 member A complex locus	clinvar
UGT1A10	HGNC:12531	ENSG00000242515	Q9HAW8	UDP-glucuronosyltransferase 1A10	clinvar
UGT1A3	HGNC:12535	ENSG00000288702	P35503	UDP-glucuronosyltransferase 1A3	clinvar
UGT1A5	HGNC:12537	ENSG00000288705	P35504	UDP-glucuronosyltransferase 1A5	clinvar
UGT1A6	HGNC:12538	ENSG00000167165	P19224	UDP-glucuronosyltransferase 1A6	clinvar
UGT1A7	HGNC:12539	ENSG00000244122	Q9HAW7	UDP-glucuronosyltransferase 1A7	clinvar
UGT1A8	HGNC:12540	ENSG00000242366	Q9HAW9	UDP-glucuronosyltransferase 1A8	clinvar
UGT1A9	HGNC:12541	ENSG00000241119	O60656	UDP-glucuronosyltransferase 1A9	clinvar
SPNS1	HGNC:30621	ENSG00000169682	Q9H2V7	Protein spinster homolog 1	clinvar
F12	HGNC:3530	ENSG00000131187	P00748	Coagulation factor XII	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
UGT1A10	UDP-glucuronosyltransferase 1A10	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
UGT1A3	UDP-glucuronosyltransferase 1A3	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
UGT1A5	UDP-glucuronosyltransferase 1A5	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
UGT1A6	UDP-glucuronosyltransferase 1A6	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to facilitate their inactivation and excretion from the body.
UGT1A7	UDP-glucuronosyltransferase 1A7	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
UGT1A8	UDP-glucuronosyltransferase 1A8	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
UGT1A9	UDP-glucuronosyltransferase 1A9	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
SPNS1	Protein spinster homolog 1	Plays a critical role in the phospholipid salvage pathway from lysosomes to the cytosol.
F12	Coagulation factor XII	Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin.

Protein-family classification

Druggable: 9 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.9

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	7	8.4×	1e-05
Transporter	1	7.8×	0.243
Protease	1	3.7×	0.323
Other/Unknown	1	0.2×	1.000

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
UGT1A	Other/Unknown	no
UGT1A10	Enzyme (other)	yes	2.4.1.17	UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
UGT1A3	Enzyme (other)	yes	2.4.1.17	UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
UGT1A5	Enzyme (other)	yes	2.4.1.17	UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
UGT1A6	Enzyme (other)	yes	2.4.1.17	UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
UGT1A7	Enzyme (other)	yes	2.4.1.17	UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
UGT1A8	Enzyme (other)	yes	2.4.1.17	UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
UGT1A9	Enzyme (other)	yes	2.4.1.17	UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
SPNS1	Transporter	yes		MFS, MFS_dom, MFS_trans_sf
F12	Protease	yes	3.4.21.38	Kringle, Fibronectin_type1, FN_type2_dom

Expression context

Cohort genes with no expression data: 2.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	7
unknown	3

Top tissues across cohort

Tissue	Cohort genes
liver	3
right lobe of liver	3
mucosa of transverse colon	2
rectum	2
adult mammalian kidney	2
duodenum	1
esophagus mucosa	1
lower esophagus mucosa	1
male germ line stem cell (sensu Vertebrata) in testis	1
gall bladder	1
granulocyte	1
monocyte	1
stromal cell of endometrium	1
gingival epithelium	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
UGT1A
UGT1A10	60	tissue_specific	marker	mucosa of transverse colon, duodenum, rectum
UGT1A3
UGT1A5		tissue_specific
UGT1A6	88	broad	marker	liver, right lobe of liver, adult mammalian kidney
UGT1A7	68	tissue_specific	marker	lower esophagus mucosa, esophagus mucosa, male germ line stem cell (sensu Vertebrata) in testis
UGT1A8	44	tissue_specific	marker	mucosa of transverse colon, rectum, gall bladder
UGT1A9	45	tissue_specific	marker	adult mammalian kidney, right lobe of liver, liver
SPNS1	144	ubiquitous	yes	granulocyte, stromal cell of endometrium, monocyte
F12	191	broad	marker	right lobe of liver, liver, gingival epithelium

Protein interactions among cohort

Intra-cohort edges: 5.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
F12	3,850
UGT1A6	1,415
UGT1A10	1,373
UGT1A7	1,312
SPNS1	1,293
UGT1A8	1,277
UGT1A3	855
UGT1A5	829
UGT1A9	26
UGT1A	0

Intra-cohort edges

A	B	Sources
UGT1A10	UGT1A7	biogrid_interaction, intact
UGT1A10	UGT1A9	biogrid_interaction, intact
UGT1A3	UGT1A5	biogrid_interaction, intact
UGT1A7	UGT1A8	biogrid_interaction, intact
UGT1A7	UGT1A9	biogrid_interaction, intact

Structural data

PDB: 2 · AlphaFold-only: 7 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
F12	P00748	17
SPNS1	Q9H2V7	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
UGT1A9	O60656	92.26
UGT1A10	Q9HAW8	92.11
UGT1A7	Q9HAW7	91.76
UGT1A3	P35503	91.59
UGT1A8	Q9HAW9	91.56
UGT1A5	P35504	91.53
UGT1A6	P19224	91.50

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 10 evidence-associated genes (8 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 8 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Glucuronidation	7	666.2×	1e-19	UGT1A10, UGT1A3, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9
Aspirin ADME	6	237.9×	1e-13	UGT1A3, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9
Paracetamol ADME	3	158.6×	3e-06	UGT1A10, UGT1A6, UGT1A9
Aggregated β-amyloid induces FXII autocatalysis	1	713.8×	0.005	F12
Defective factor XII causes hereditary angioedema	1	356.9×	0.006	F12
Defective SERPING1 causes hereditary angioedema	1	356.9×	0.006	F12
NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis	1	178.4×	0.008	UGT1A3
Atorvastatin ADME	1	178.4×	0.008	UGT1A3
Prednisone ADME	1	158.6×	0.008	UGT1A3
Regulation of FXIIa and plasma kallikrein activity	1	142.8×	0.008	F12
FXIIa, PKa-dependent activation of coagulation pathway	1	142.8×	0.008	F12
FXIIa activates plasma kallikrein-kinin system	1	21.6×	0.049	F12
PPARA activates gene expression	1	11.8×	0.082	UGT1A9

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 9 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
flavone metabolic process	4	7489.8×	0e+00	UGT1A10, UGT1A7, UGT1A8, UGT1A9
toxin catabolic process	2	3744.9×	0e+00	UGT1A10, UGT1A7
negative regulation of fatty acid metabolic process	6	2808.7×	0e+00	UGT1A10, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9
flavonoid metabolic process	4	936.2×	2e-11	UGT1A3, UGT1A7, UGT1A8, UGT1A9
xenobiotic metabolic process	6	99.4×	4e-11	UGT1A10, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9
retinoic acid metabolic process	4	356.7×	1e-09	UGT1A3, UGT1A7, UGT1A8, UGT1A9
liver development	4	98.5×	2e-07	UGT1A10, UGT1A7, UGT1A8, UGT1A9
glucuronate metabolic process	2	1872.4×	1e-06	UGT1A10, UGT1A6
coumarin metabolic process	2	624.1×	1e-05	UGT1A7, UGT1A8
estrogen metabolic process	2	138.7×	3e-04	UGT1A3, UGT1A7
xenobiotic catabolic process	2	124.8×	3e-04	UGT1A10, UGT1A7
steroid metabolic process	2	74.9×	8e-04	UGT1A5, UGT1A8
plasma kallikrein-kinin cascade	1	936.2×	0.002	F12
negative regulation of steroid metabolic process	1	936.2×	0.002	UGT1A8
vitamin D3 metabolic process	1	936.2×	0.002	UGT1A3
fatty acid metabolic process	2	43.0×	0.002	UGT1A7, UGT1A8
Factor XII activation	1	624.1×	0.003	F12
response to misfolded protein	1	624.1×	0.003	F12
bile acid secretion	1	374.5×	0.004	UGT1A3
positive regulation of fibrinolysis	1	374.5×	0.004	F12
lysophospholipid transport	1	374.5×	0.004	SPNS1
blood coagulation, intrinsic pathway	1	234.1×	0.006	F12
obsolete regulation of lysosomal lumen pH	1	234.1×	0.006	SPNS1
positive regulation of plasminogen activation	1	208.1×	0.007	F12
positive regulation of blood coagulation	1	124.8×	0.010	F12
phospholipid efflux	1	124.8×	0.010	SPNS1
fibrinolysis	1	93.6×	0.013	F12
zymogen activation	1	74.9×	0.016	F12
protein autoprocessing	1	72.0×	0.016	F12
blood coagulation	1	19.3×	0.055	F12

Therapeutics

Drug target analysis

Approved (phase 4): 4 · Phase ≥3: 5 · Phased (≥1): 5 · Undrugged: 5

Druggability breadth: 8 of 10 evidence-associated genes (80%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
UGT1A10	DICLOFENAC
UGT1A6	DICLOFENAC
UGT1A7	DICLOFENAC
UGT1A9	DICLOFENAC

Top cohort targets by molecule count

Symbol	Molecules	Max phase
F12	3	3
UGT1A10	2	4
UGT1A6	2	4
UGT1A7	2	4
UGT1A9	1	4
UGT1A	0	0
UGT1A3	0	0
UGT1A5	0	0
UGT1A8	0	0
SPNS1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
DICLOFENAC	4	UGT1A10, UGT1A6, UGT1A7, UGT1A9
TROGLITAZONE	4	UGT1A6
PROBENECID	4	UGT1A7
NAFAMOSTAT	3	F12
GABEXATE	3	F12
EPIESTRIOL	2	UGT1A10
SEPIMOSTAT	2	F12

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 8.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
UGT1A9	153	ADMET:149, Binding:4
UGT1A3	131	ADMET:129, Binding:2
F12	128	Binding:123, Functional:3, ADMET:2
UGT1A10	101	ADMET:99, Binding:2
UGT1A8	87	ADMET:86, Binding:1
UGT1A6	76	ADMET:71, Binding:5
UGT1A7	76	ADMET:74, Binding:2
UGT1A5	35	ADMET:35

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
UGT1A10	2.4.1.17	glucuronosyltransferase
UGT1A3	2.4.1.17	glucuronosyltransferase
UGT1A5	2.4.1.17	glucuronosyltransferase
UGT1A6	2.4.1.17	glucuronosyltransferase
UGT1A7	2.4.1.17	glucuronosyltransferase
UGT1A8	2.4.1.17	glucuronosyltransferase
UGT1A9	2.4.1.17	glucuronosyltransferase
F12	3.4.21.38	coagulation factor XIIa

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
UGT1A10	101
UGT1A3	131
UGT1A9	153
F12	128

Pharmacogenomics

Cohort genes with a PharmGKB record: 10; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

7 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
DICLOFENAC	4	UGT1A10, UGT1A6, UGT1A7, UGT1A9
TROGLITAZONE	4	UGT1A6
PROBENECID	4	UGT1A7
NAFAMOSTAT	3	F12
GABEXATE	3	F12
EPIESTRIOL	2	UGT1A10
SEPIMOSTAT	2	F12

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	4	UGT1A10, UGT1A6, UGT1A7, UGT1A9
B	Phased (≥1) drug, not yet approved	1	F12
C	Druggable family + PDB, no drug	1	SPNS1
D	Druggable family + AlphaFold only, no drug	3	UGT1A3, UGT1A5, UGT1A8
E	Difficult family or no structure, no drug	1	UGT1A

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
UGT1A3	131	—
UGT1A	0	—
UGT1A5	35	—
UGT1A8	87	—
SPNS1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 30.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	22
PHASE2	4
PHASE3	2
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00288600	PHASE4	COMPLETED	Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
NCT00360204	PHASE3	COMPLETED	Improving Health Outcomes for New Mothers and Babies
NCT00653874	PHASE3	COMPLETED	Transcutaneous Bilirubinometry in Healthy Term and Near-Term Neonates
NCT00004381	PHASE2	COMPLETED	Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia
NCT00004382	PHASE2	COMPLETED	Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns
NCT00115544	PHASE2	COMPLETED	Safety and Pharmacology of Stanate
NCT03564678	PHASE2	TERMINATED	Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia
NCT01550627	EARLY_PHASE1	COMPLETED	Effect of Intravenous Fluid Supplementation on Serum Bilirubin and Cardiorespiratory Parameters in Preterm Infants During Phototherapy
NCT06421844	Not specified	RECRUITING	A Prospective Study: Smart Phone Application for Measure Serum Bilirubin Through Sclera Images
NCT07409194	Not specified	ENROLLING_BY_INVITATION	The Effect of Acupressure on Hyperbilirubinemia in Newborns: A Randomized Controlled Trial
NCT00076960	Not specified	NO_LONGER_AVAILABLE	Compassionate Use of Stanate (TM) [Stannsoporfin]
NCT00383318	Not specified	COMPLETED	Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia
NCT00635375	Not specified	COMPLETED	Comparative Study of Phototherapy for Hyperbilirubinemia
NCT00741117	Not specified	TERMINATED	Conjugated Hyperbilirubinemia and Pulse Oximetry
NCT01136577	Not specified	TERMINATED	Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn
NCT01622699	Not specified	COMPLETED	Implementation of a Transcutaneous Bilirubinometer
NCT01746511	Not specified	COMPLETED	Glycerin Suppositories to Reduce Jaundice in Premature Infants
NCT01944696	Not specified	UNKNOWN	Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants?
NCT02446951	Not specified	COMPLETED	Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department
NCT02612207	Not specified	COMPLETED	Point-of-Care System for Determination of Bilirubin Capacity in Neonates
NCT02613676	Not specified	COMPLETED	Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns
NCT02685189	Not specified	TERMINATED	Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)
NCT02691156	Not specified	COMPLETED	Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
NCT02712138	Not specified	WITHDRAWN	Biomarker for Gilbert Disease (BioGilbert)
NCT02774434	Not specified	COMPLETED	Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age
NCT02805296	Not specified	COMPLETED	High Intensity Phototherapy: Double vs. Single
NCT03195998	Not specified	COMPLETED	Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants
NCT04271098	Not specified	COMPLETED	The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries
NCT04897113	Not specified	UNKNOWN	Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old
NCT07098234	Not specified	COMPLETED	Effect of Vitamin-D as an Adjuvant to Phototherapy in Reduction of Indirect Serum Bilirubin

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GLYCERIN	4	1
LEVOCARNITINE	4	1
STANNSOPORFIN	3	3
CARNITINE	3	1
VITAMIN B COMPLEX	3	1
DEXTROCARNITINE	0	1